GeneDx Taps Quest Diagnostics Executive as President to Drive Scale
Event summary
- GeneDx appointed Mark Gardner as President effective June 15, 2026.
- Gardner previously led molecular genomics and oncology at Quest Diagnostics.
- He also served as CEO of OmniSeq, acquired by Labcorp.
- Gardner will oversee commercial and operations teams to scale efficiently.
- GeneDx aims to strengthen execution in genomic medicine leadership.
The big picture
GeneDx's appointment of Mark Gardner underscores its push to scale operations and strengthen commercial execution in the competitive genomics market. Gardner's background in molecular genomics and oncology at Quest Diagnostics, along with his leadership at OmniSeq, positions him to drive growth in rare disease diagnostics and precision medicine. The move reflects broader industry trends toward consolidating expertise in genomic data and advanced diagnostic testing.
What we're watching
- Scale Execution
- How Gardner's experience at Quest Diagnostics will translate to GeneDx's operational efficiency and commercial growth.
- Market Leadership
- Whether GeneDx can sustain its position as a leader in rare disease diagnosis amid increasing competition.
- Strategic Expansion
- The pace at which GeneDx integrates Gardner's precision medicine expertise into its long-term strategy.
Related topics